Company intelligence / Profile preview
NeuroBo Pharmaceuticals
Medford, Massachusetts, United Statesneurobopharma.com ↗
- Ownership
- Public · NRBO
- Development stage
- Phase 1
01
Overview
NeuroBo Pharmaceuticals—now rebranding to MetaVia—is a clinical-stage biotech focused on cardiometabolic diseases. Its lead programs are DA‑1241, a GPR119 agonist in Phase IIa trials for MASH/NASH with promising interim results expected by mid-to-late 2024, and DA‑1726, an oxyntomodulin analogue dual agonist targeting GLP1R/GCGR currently in early clinical development for obesity. The company has shifted away from its original focus on neurodegenerative diseases following its merger with Gemphire Therapeutics. It has strategic partnerships with Dong-A ST and ImmunoForge to advance its pipeline using innovative drug delivery platforms.
- Therapeutic areas
- EndocrinologyNeurologyMetabolic Disorders
- Modalities
- Small molecules (e.g., DA‑1241)Peptides/biologics (e.g., DA‑1726, an oxyntomodulin analogue)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Dong-A ST Co. Ltd. – licensing partner and largest shareholder; provides pipeline assets including DA‐1241 & DA‐1726.ImmunoForge – joint research agreement to develop long-lasting formulations using ELP technology.
04
Financials
- Market cap
- $20.3M
- Total revenue
- $0
- Enterprise value
- $7.9M
Beyond the preview
Go deeper on NeuroBo Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroBo Pharmaceuticals.